Clinical trial

Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-IIIB NSCLC (MDT-BRIDGE)

NCT05925530

Study summary

ClinicalTrials.gov

Design: INTERVENTIONAL · Status: ACTIVE NOT RECRUITING · Phase: PHASE2

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

1 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Mapped RxNorm record Durvalumab Normalized identity: durvalumab View linked drug · Find medicine records · Find other trials using this name

StatusACTIVE_NOT_RECRUITING

Study typeINTERVENTIONAL

Start date2024-02-22

PhasePHASE2

Conditions

Non-small Cell Lung Cancerverified · MONDO: non-small cell lung carcinoma

Interventions

DurvalumabDRUG · verified · RxNorm: durvalumab

Sponsors & collaborators

AstraZenecalead sponsor

Mapped research locations

MadridSpain3 MilanItaly3 PragueCzechia2 ViennaAustria2 LisbonPortugal2 HoustonTexas, United States1 BarcelonaSpain1 ParisFrance1 BerlinGermany1 MontrealQuebec, Canada1 BudapestHungary1 The BronxNew York, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05925530 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.